Vasopressin
Pitressin, Vasopressin, Vasostrict (vasopressin) is a protein pharmaceutical. Vasopressin was first approved as Pitressin tannate on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Vasopressin, Vasostrict (discontinued: Pitressin, Vasopressin, Vasostrict)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vasopressin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VASOPRESSIN | American Regent | N-212593 RX | 2020-08-03 | 2 products, RLD, RS |
| VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Baxter | N-217569 RX | 2023-09-29 | 2 products, RLD, RS |
| VASOSTRICT | Endo | N-204485 RX | 2014-04-17 | 4 products, RLD, RS |
| VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Long Grove Pharmaceuticals | N-217766 RX | 2024-07-11 | 2 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vasopressin | ANDA | 2025-08-26 |
| vasopressin in 0.9% sodium chloride | New Drug Application | 2025-06-17 |
| vasostrict | New Drug Application | 2023-11-16 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Vasopressin, Vasostrict, Par Sterile Products | |||
| 9375478 | 2035-01-30 | U-1857 | |
| 9687526 | 2035-01-30 | U-1857 | |
| 9744209 | 2035-01-30 | U-1857 | |
| 9744239 | 2035-01-30 | U-1857 | |
| 9750785 | 2035-01-30 | DP | |
| 9919026 | 2035-01-30 | DP | |
| 9925233 | 2035-01-30 | U-1857 | |
| 9925234 | 2035-01-30 | U-1857 | |
| 9937223 | 2035-01-30 | U-1857 | |
| 9962422 | 2035-01-30 | U-1857 | |
| 9968649 | 2035-01-30 | U-1857 | |
| 9974827 | 2035-01-30 | U-1857 | |
| 9981006 | 2035-01-30 | U-1857 | |
| 10010575 | 2035-01-30 | U-1857 | |
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03X: Other diuretics in atc
— C03XA: Vasopressin antagonists, diuretics
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01B: Posterior pituitary lobe hormones
— H01BA: Vasopressin and analogues
— H01BA01: Vasopressin (argipressin)
HCPCS
No data
Clinical
Clinical Trials
406 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes insipidus | D003919 | — | E23.2 | 6 | 13 | 11 | 12 | 29 | 67 |
| Septic shock | D012772 | — | A48.3 | 1 | 11 | 11 | 9 | 16 | 44 |
| Shock | D012769 | — | R57.1 | 1 | 13 | 12 | 6 | 17 | 43 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 4 | 2 | 17 | 7 | 30 |
| Syndrome | D013577 | — | — | 2 | 6 | 10 | 3 | 9 | 27 |
| Hyponatremia | D007010 | — | E87.1 | — | 2 | 13 | 2 | 9 | 26 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 6 | 4 | 6 | 11 | 24 |
| Hepatorenal syndrome | D006530 | — | K76.7 | 1 | 4 | 8 | 3 | 6 | 20 |
| Acute kidney injury | D058186 | — | N17 | — | 2 | 3 | 5 | 9 | 19 |
| Nocturia | D053158 | — | R35.1 | — | 4 | 8 | 4 | 4 | 19 |
Show 64 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inappropriate adh syndrome | D007177 | EFO_1000982 | E22.2 | 1 | 3 | 6 | — | 4 | 13 |
| Neurogenic diabetes insipidus | D020790 | — | — | 2 | 3 | 1 | — | 5 | 11 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 3 | 4 | — | 3 | 9 |
| Polycystic kidney diseases | D007690 | — | Q61.3 | — | 3 | 4 | — | 2 | 8 |
| Autosomal dominant polycystic kidney | D016891 | EFO_1001496 | Q61.2 | — | 3 | 4 | — | 2 | 8 |
| Liver failure | D017093 | — | K72.9 | — | 1 | 1 | — | 5 | 7 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | 1 | — | 3 | 6 |
| Hepatic insufficiency | D048550 | — | — | — | — | 1 | — | 4 | 5 |
| Critical illness | D016638 | — | — | — | 1 | 1 | — | 3 | 5 |
| Anesthesia | D000758 | — | — | — | 1 | 1 | — | 3 | 4 |
Show 26 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | — | — | 2 | 4 |
| Nephrogenic diabetes insipidus | D018500 | — | N25.1 | — | 1 | — | — | 3 | 4 |
| Depression | D003863 | — | F33.9 | 1 | 1 | — | — | 1 | 3 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | 2 | 3 |
| Hemophilia b | D002836 | — | D67 | 1 | 1 | — | — | 1 | 3 |
| Cerebral hemorrhage | D002543 | — | — | — | 2 | — | — | — | 2 |
| Traumatic shock | D012774 | — | T79.4 | 1 | 1 | — | — | — | 2 |
| Nephritis | D009393 | — | N05 | — | 1 | — | — | — | 1 |
| Neonatal sepsis | D000071074 | — | — | — | 1 | — | — | — | 1 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | 11 | 16 |
| Social psychology | D011593 | — | — | 2 | — | — | — | — | 2 |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | 1 | — | — | — | 1 | 2 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 2 | — | — | — | — | 2 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Embolism | D004617 | — | — | 1 | — | — | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | — | — | — | — | 1 |
| Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | 1 | — | — | — | — | 1 |
| Fear | D005239 | — | — | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dehydration | D003681 | — | E86.0 | — | — | — | — | 4 | 4 |
| Acute-on-chronic liver failure | D065290 | — | — | — | — | — | — | 4 | 4 |
| Blood platelet disorders | D001791 | — | — | — | — | — | — | 2 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
| Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | — | — | — | — | 2 | 2 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | — | — | 2 | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 2 | 2 |
| Acute liver failure | D017114 | — | — | — | — | — | — | 2 | 2 |
| Meniere disease | D008575 | EFO_0006862 | H81.0 | — | — | — | — | 2 | 2 |
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | — | — | — | 2 | 2 |
Show 77 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vasopressin |
| INN | vasopressin injection |
| Description | Argipressin is the predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. It has a role as a cardiovascular drug, a hematologic agent and a mitogen. It is a conjugate base of an argipressin(2+). |
| Classification | Protein |
| Drug class | vasoconstrictors (vasopressin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 113-79-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL373742 |
| ChEBI ID | 34543 |
| PubChem CID | 644077 |
| DrugBank | DB00067 |
| UNII ID | Y87Y826H08 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Vasopressin – Eagle Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 62,326 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,107 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use